Bactiguard Holding Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Bactiguard Holding is forecast to grow earnings and revenue by 67% and 7.5% per annum respectively. EPS is expected to grow by 67.1% per annum. Return on equity is forecast to be -10.9% in 3 years.
Anahtar bilgiler
67.0%
Kazanç büyüme oranı
67.1%
EPS büyüme oranı
Medical Equipment kazanç büyümesi | 22.8% |
Gelir büyüme oranı | 7.5% |
Gelecekteki özkaynak getirisi | -10.9% |
Analist kapsamı | Low |
Son güncelleme | 14 Feb 2024 |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2025 | 237 | -28 | N/A | N/A | 1 |
12/31/2024 | 212 | -79 | N/A | N/A | 1 |
12/31/2023 | 204 | -138 | -61 | -52 | N/A |
9/30/2023 | 211 | -125 | -62 | -55 | N/A |
6/30/2023 | 224 | -109 | -23 | -11 | N/A |
3/31/2023 | 233 | -58 | -4 | 7 | N/A |
12/31/2022 | 227 | -53 | -8 | 3 | N/A |
9/30/2022 | 209 | -64 | -24 | -16 | N/A |
6/30/2022 | 193 | -66 | -13 | -11 | N/A |
3/31/2022 | 186 | -65 | -8 | -4 | N/A |
12/31/2021 | 172 | -59 | 0 | 7 | N/A |
9/30/2021 | 216 | -44 | 10 | 23 | N/A |
6/30/2021 | 203 | -50 | -11 | 5 | N/A |
3/31/2021 | 170 | -38 | -14 | 3 | N/A |
12/31/2020 | 177 | -38 | -15 | 1 | N/A |
9/30/2020 | 155 | -26 | 26 | 34 | N/A |
6/30/2020 | 187 | 14 | 55 | 61 | N/A |
3/31/2020 | 206 | 9 | 53 | 57 | N/A |
12/31/2019 | 190 | 16 | 50 | 54 | N/A |
9/30/2019 | 155 | 9 | 7 | 14 | N/A |
6/30/2019 | 128 | -15 | -10 | -4 | N/A |
3/31/2019 | 149 | -10 | 0 | 7 | N/A |
12/31/2018 | 150 | -15 | -5 | 1 | N/A |
9/30/2018 | 160 | -10 | -6 | 1 | N/A |
6/30/2018 | 159 | -10 | -4 | 3 | N/A |
3/31/2018 | 143 | -15 | -12 | -5 | N/A |
12/31/2017 | 151 | -3 | 0 | 6 | N/A |
9/30/2017 | 142 | -10 | N/A | -8 | N/A |
6/30/2017 | 142 | -10 | N/A | -14 | N/A |
3/31/2017 | 140 | -12 | N/A | -18 | N/A |
12/31/2016 | 124 | -27 | N/A | -12 | N/A |
9/30/2016 | 116 | -39 | N/A | -18 | N/A |
6/30/2016 | 139 | -32 | N/A | -6 | N/A |
3/31/2016 | 133 | -34 | N/A | -11 | N/A |
12/31/2015 | 135 | -27 | N/A | -21 | N/A |
9/30/2015 | 120 | -39 | N/A | -30 | N/A |
6/30/2015 | 87 | -61 | N/A | -60 | N/A |
3/31/2015 | 88 | -95 | N/A | -62 | N/A |
12/31/2014 | 95 | -111 | N/A | -36 | N/A |
9/30/2014 | 137 | -60 | N/A | -47 | N/A |
6/30/2014 | 143 | -50 | N/A | -28 | N/A |
3/31/2014 | 136 | -20 | N/A | -25 | N/A |
12/31/2013 | 129 | -3 | N/A | -45 | N/A |
9/30/2013 | 110 | -20 | N/A | -54 | N/A |
6/30/2013 | 104 | -32 | N/A | -54 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 0QV2 is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: 0QV2 is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: 0QV2 is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: 0QV2's revenue (7.5% per year) is forecast to grow faster than the UK market (3.3% per year).
Yüksek Büyüme Geliri: 0QV2's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 0QV2 is forecast to be unprofitable in 3 years.